November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Paolo Tarantino: Honored to co-chair the New Drugs on the Horizon Session at the EORTC-NCI-AACR Triple Meeting
Oct 26, 2024, 09:26

Paolo Tarantino: Honored to co-chair the New Drugs on the Horizon Session at the EORTC-NCI-AACR Triple Meeting

Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared on LinkedIn:

“Such a honor to co-chair the New Drugs on the Horizon Session with Timothy Yap at the EORTC-NCI-AACR Triple Meeting.

Brings hope to see so much innovation in the oncology pipeline, with novel ADCs, IO and targeted drugs all promising to help us treat cancer better.

Soon.”

Paolo Tarantino

More posts featuring Paolo Tarantino on oncodaily.com

Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.